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The Role of Basophils in Inflammatory Reactions 
LAWRENCE M. LICHTENSTEIN, M.D, GIANNI MARONE, M.D., LARRY L. THOMAS, PH.D., AND 
FLOYD J. MALVEAUX, M.D. 
Department of Medicine, Division of Clinical Immu.nology, The Johns Hoplzins University, School of M edicine at the Good Samaritan 
Hospital, Baltimore, Mw y land, U.S.A. 
This review demonstrates that basophils reflect skin 
and lung mast cell reactivity and show characteristic 
changes in mediator release associated with clinical dis-
ease. Although the numbers of IgE molecules and IgE 
receptors on basophils have been enumerated, these 
have, in most instances, little influence on the release of 
histamine after challenge. There is, rather, a parameter 
of "releasability" that may be a major variable in allergic 
disease states. Basophils contain and release histamine, 
the eosinophil chemotactic factor of anaphylaxis (ECF-
A), a slowly reacting substance of anaphylaxis (SRS-A), 
and a kallikrein. The release process is controlled by 
hormone-basophil receptor interactions that determine 
the cyclic AMP levelj plasma and tissue adenosine levels 
appear prominent in this control. Histamine feeds back 
to negatively modulate basophil and mast cell release 
through a specific histamine 2-receptorj it also inhibits 
lymphocyte and neutrophil function. Like neutrophils, 
basophils contain beta-glucuronidase while neutrophils 
contain SRS-A and a low-molecular-weight ECF. The 
stimuli for primary basophil and neutrophil release are, 
however, quite different, although phagocytic sti:t~uli, 
which fail to cause basophil mediator release, potentiate 
the IgE response. It is concluded that basophils play a 
significant in vivo role in inflammation by acting as an 
interface between foreign antigens, the serum cascade 
systems, and other inflammatory cells. 
Perhaps more than any other blood-borne cell t~p~, the 
functional role of the basophil remains enigmatic. ThIS IS not 
because studies of this cell type are laclOng; it is well known, for 
example, that the basophil cell membrane contains receptors 
for IgE antibody and that granule-associated mediators are 
released on contact with antigen. Rathel', it is because of the 
basophils sparse representation, constituting, as it does, less 
than 1% of the leukocyte population. Because of this low 
percentage and because of the failure, to date, to purify normal 
basophils, its physical features, biochemical properties, . and 
subsequently, its importance in the overall defense mechamsms 
of the body, remain uncertain. One of the curious features of 
the basophil is that, although its origins are different from t~lOse 
of the tissue mast cell, it has evolved capacities essentially 
similar to those of the tissue mast cell. Although there are 
differences in the functions of the 2 cell types, these fade in 
importance as one considers the marked similarities. The rela-
tionship between these 2 cell types is reinforced by the fact that 
as one surveys the mammalian species there seems to be an 
inverse ratio between the numbers of circulating basophils and 
tissue-fixed mast cells [1]. Moreover, the recent work of Asken-
ase and Dvorak on cutaneous basophil hypersensitivity points 
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out an important tissue function of the basophil that may, in 
the end, overshadow the functions of this cell type in the 
ci.r'culatory system [2,3]. In spite of these uncertainties, the 
basophil remains of vital interest and it may play an important 
role in both physiological and pathological processes. 
RELATIONSHIP BETWEEN BASOPHIL FUNCTION 
AND SYSTEMIC RESPONSIVENESS 
The assumption that the basophil is an important in vivo 
component of the inflammatory process is rendered more likely 
by the rather faithful fashion in which basophil function par-
allels systemic responsiveness. The basophil and the mast cell 
seem to be equally endowed with respect to sUlface represen-
tation of IgE antibody. There is, therefore, an excellent quan-
titative relationship between the response of basophils to anti-
gen, manifested by histamine release, and the response of skin 
mast cells to intradermal antigen administration, manifested by 
the wheal and flare reaction [4]. There is a similar quantitative 
correlation between either skin test results or basophil hista-
mine release and the response of lung mast cells, as measured 
by changes in airway conductance on inhalational challenge 
[5]. Moreover, the response of the basophil to antigen reflects 
systemic disease. Thus, it can be shown that the quantity of 
antigen required for 50% histamine release varies in patients 
with ragweed hay fever over 4 orders of magnitude. This 
sensitivity is correlated in a highly significant fashion with the 
degree of symptomatology manifested by these patients during 
the ragweed season [6]. 
Another example is that of chronic idiopathic urticaria. In 
this disease, the causes of which are unknown, the patients' 
basophils are clearly hyporesponsive, as compared to cells 
obtained from control populations [7] (Fig 1), to immunologic 
stimulation by anti-IgE. The reasons for this decrease in reac-
tivity are not clear, but we have suggested that it reflects in 
vivo release and thus results from functional desensitization; 
i.e., cells that have released a portion of their histamine become 
unresponsive to further stimulation. This concept is reinforced 
by the observation that the basophils of patients with Ul'ticaria 
have significantly less histamine than cells from normal indi-
viduals; about 0.7 ± 0.1 versus 1.3 ± 0.3 pg per basophil [7]. 
Whatever the mechanism, this is another instance of basophil 
function mirroring a systemic disease process. 
IgE RECEPTORS ON THE BASOPHIL MEMBRANE 
The basophil and the mast cell are the only cell types that 
have surface receptors for the Fc portion of IgE immunoglob-
ulins. Because of obvious difficulties in obtaining these cells, 
the nature of this receptor has not been studied in human 
basophils. However, studies with a line ofleukemic rat basophils 
and rat mast cells have revealed that the receptor is an asym-
metric molecule with a molecular size of about 150,000 daltons 
[8-10). The isolated receptor molecule retains the a~ility to 
combine with IgE, and equilibrium constants of approxll11ately 
10 10 M IL have been noted for this interaction [10]. Preliminary 
data indicate that the cross-linking of these receptors by anti-
receptor antibody can trigger the cell to release histamine 
[11). It is well known that histamine release requires bivalent 
antigen, and there is good evidence that cross-linking of the IgE 
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FIG 1. Anti-IgE-induced histamine release from the basophils of 20 
patients with chronic idiopathic urticaria compared to that in 23 
controls. The patients and controls had a similar range and mean in 
terms of age and were matched with respect to sex. 
antibody by antigen provides the stimulation for this process 
[12]. It now seems likely that the first event in the basophil 
release reaction is an approximation of the cell membrane Fc 
receptors. 
The number of IgE molecules per basophil, ranging from 
3,000 to 6~0,000, is quantitatively related to the serum IgE 
concentratIOn (r = 0.94) [13]. The number of receptors for IgE 
on human basophils has a similar range (15,000 to about 
600,000), and the degree ofreceptor saturation is also a function 
of the serum IgE level (r = 0.84) [43]. More surprisingly, the 
total number of IgE receptors is also closely related to the 
serum IgE level (r = 0.92) [43]. The basis for this association 
between the serum IgE level and its receptor on basophils, i.e. , 
whet~er .it consists of receptor modulation by serum IgE or a 
genetiC hnkage between the 2 parameters is unknown. The 
equilibrium constant for the reaction betw~en human IgE and 
the. basoph~ re~eptor ranges from about 109 - 1OIoM/ L [44]. 
ThIS VarlatlOn m receptor affinity for IgE is unrelated to the 
s:ruJ? IgE concentr~tion and appears to be rather normally 
dlstnbuted on both sldes of the mean of approximately 7 X 109 
MIL. Thu.s, there is heterogeneity with respect to the affinity 
of basophil receptors for IgE. Preliminary data also indicate 
that. there is h:terogeneity in the IgE antibody molecules 
obtamed from different patients; there is a two- to threefold 
difference in the ability of different sera (normalized to contain 
the sa~e IgE antibody and total IgE) to passively sensitize 
basophils from a normal donor for histamine release. Both 
eleme.nts of heterogeneity may well be important to an under-
standmg of the allergic responses of man. 
BASOPHIL "RELEASABILITY" 
We have been particularly interested in the relationship 
between the number of IgE molecules per basophil and the 
r~sP.onse ofth~se c~lls to immunologic challenge. The surprising 
fmdmg of studies directed to this question is that it takes a very 
few molecules of IgE to fully prepare the basophils for maximal 
histamine release. This number has been quantified with re-
spect to anti-IgE challenge; approximately 3,000 to 4,000 mol-
ecules ~f IgE per baso.phil can produce a cell that is as fully 
responslv~ as B: cell With 500,000 IgE molecules [13] (Fig 2). 
Thls relatIOnship has not been fully evaluated with respect to 
IgE antibody, but preliminary studies suggest that the mini-
mum numbe~ for maximal sensitization is probably less than 
1,000 IgE antibody molecules per cell. Thus the marked vari-
ability in basophil sensitivity to antigen and in the amount of 
hi~tam~ne that a. cell is capable of releasing is likely to be 
pnmaril~ a r~flectlOn not of immunologic differences, but rather 
o~ a baSIC diffe~ence in basophil "releasability." We are con-
vmce~ that an ~portant parameter of human responsiveness 
to varlO~s. basop~il and mast cell stimuli is this vaguely defined 
releasabih~y, which reflects the total ability of the cell to 
r.espond WIth the release of different mediators [14]. It seems 
lIkely that releasability will be an important element in an 
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understanding of diseases such as asthma or urticaria; a signifi-
cant variable may be the relative ease with which the mast cells 
of these patients release mediators in response to nonspecific \ 
stimuli. In this hypothesis, of course, we assume that basophil 
and mast cell releasability vary concordantly; this idea has not 
been proved, but it seems likely on the basis of the arguments 
laid out above. 
BASOPHIL AND MAST CELL MEDIATORS 
Another strong statement to support the similarity between \ 
basophils and mast cells is that they.contain a relatively similar 
complement of mediators. Both cell types are largely filled with 
histamine-containing granules that can be released by appro-
priate stimuli. It has been demonstrated recently that both cell 
types also contain 2 other mediators that may play a role in 
allergic reactions, the eosinophil chemotactic factor of anaphy-
laxis (ECF-A) and the slow reacting substance of anaphylaxis 
(SRS-A) [15-18]. The importance of the eosinophil in inflam-
matory diseases is a fascinating question that will, of course, be \ 
dealt with by others in this volume. Both basophils and mast 
cells contain a variety of low-molecular-weight factors that are 
potent chemotactic agents and highly specific for eosinophils. 
The number and nature of these factors has not yet been 
delineated. Similarly, despite almost 10 years of effort, the exact 
chemical nature of SRS-A remains undefined, although the 
studies of Orange et al suggest that it is a low-molecular-weight, 
sulfur-containing lipid [19]. Whether there aTe more than 1 
SRS-A and whether some or all of these mediators are products 
of arachidonic acid metabolism also remains to be established. 
One of the most interesting mediators recently identified as 
being represented in- the basophil, and probably in mast cells 
is a kallikrein [20]. This high-molecular-weight enzyme is usu: 
ally assayed by means of its ability to hydrolize a synthetic \ 
substrate, tosyl arginine methyl ester (TAMe) . Recent studies 
by Newball and Talamo indicate, however, that the esterase 
activity and the ability to split a kinin-like molecule from serum 
kininogen are subserved by the same molecule. The nature of 
the kinin generated has not been studied, but it is identified by 
its ability to react with an antibody that specifically recogniz~s 
the nonapeptide bradykinin. The basophil kallikrein represents 
the only immunologic mechanism for the activation of the 
kallikreinkinin system and thus places this system, which h a 
been elegantly described in chemical terms, in a somewhat \ 
mOl:e biolo~ical perspective [21]. A related feature of anaphy-
lactIC reactIOns that has not yet been fully studied is the ability 
of IgE-mediated reactions to activate the coagulation sequenc~. 
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FIG 2. Histamine release as a function of anti-IgE concentration. 
Similar dose-response curves were obtained from patients whose ha· 
sophils contained 3900 (A), 5300 (e), and 249,000 (0) molecules of 19E 
per basophil. 
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Clotting changes have been observed in rabbit anaphylaxis by 
Pinkard, Tanigawa, and Halonen [22], and our own studies of 
human anaphylaxis have uncovered similar changes [23]. It 
seems conceivable that the basophil kallikrein interacts not 
only with the high-molecular-weight kininogen, but also with 
Hageman factor, for which the high-molecular-weight kinino-
gen is a cofactor. If this were the case, we would have a ready 
explanation for the changes in coagulation ability noted during 
anaphylactic reactions. 
THE BIOCHEMICAL MECHANISM(S) OF 
MEDIATOR RELEASE 
Having dermed some of the immunologic parameters and 
described some of the basophil mediators, we think it appro-
priate to discuss what is known about the biochemical mecha-
nism of mediator release. The process by which basophil gran-
ules are exteriorized is similar to the secretory mechanism of 
other cells: it is an active, energy-requiring process in which 
calcium acts as the link between stimulation and secretion 
[24]. One of the more essential elements of the biochemical 
control of the secretory process in basophils is related to cyclic 
nucleotide metabolism. It was observed about a decade ago 
that agents such as beta-adrenergic agonists (e.g., isoproterenol) 
and phosphodiesterase inhibitors (e.g., theophylline) which in-
crease intracellular cyclic AMP inhibited the release of hista-
mine and other mediators [25]. Subsequent measurements in 
whole leukocyte prepal'ations showed that these drugs, at about 
the same concentrations required for the inhibition of histamine 
release [26] , increase the cyclic AMP level. The difficulty, of 
course, is that it was unclear whether the cyclic AMP levels 
being recorded had anything to do with the few basophils 
present in the leukocyte preparations. At the beginning of this 
research effort it seemed reasonable to assume that most of the 
leukocytes responded similarly to the different agonists, but we 
now know this is Dot true. Neutrophils and lymphocytes behave 
quite differently; even among lymphocytes some subclasses 
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FIG 3. The time course of changes in cyclic AMP level and histamine 
release after anti-IgE challenge of a preparation of 80% basophils. The 
remainder of the leukocytes were immature granu locytes. The inset 
shows an anti-IgE dose-response curve with the same patient's cells; 
the arrow indicates the anti-IgE concentration used for the kinetics 
experiments. 
have isoproterenol or histamine receptors and other subclasses 
lack them [27]. Nevertheless, the early data led to the hypoth-
esis that the antigen-IgE interaction leads to a transient fall in 
cyclic AMP that constitutes an early step in the release process. 
In fact, an appropriate change in cyclic AMP has been dem-
onstrated in purified rat mast cells subjected to a variety of 
stimuli, but only very recently have we been fortunate enough 
to obtain a highJy purified preparation of basophils (from a 
patient with chronic myelocytic leukemia) with which we could 
make direct measurements. In this individual's basophils (Fig 
3) there was an unanticipated, very transient rise in cyclic AMP 
about 30 sec after antigenic stimulation; by 1 min, however, 
well before the initiation of histamine release, the anticipated 
fall in cyclic AMP level occurred. 
"Recent studies by Sullivan et al with rat mast cells have 
shown the same transient rise and fall and thus have under-
scored the similarity between these 2 cell types [28]. Therefore, 
it seems likely that the in vivo secretion of histamine and other 
mediators is partially modulated by hormones that, by inter-
acting with specific receptors on mast cells and basophils, alter 
the intracellular level of cyclic AMP. Of the several endogenous 
hormones that may function in this way, the most interesting 
is histamine itself. Histamine acts on specific basophil histanline 
2-receptors to increase the cyclic AMP level and turn off 
histamine release [29]. The same phenomenon has been noted 
in mast cells: Chakrin and his colleagues have demonstrated 
that in the presence of histamine 2-antagonists, such as buri-
mamide or metiamide, there is potentiation of the release of 
histamine and other mediators from anti-IgE-challenged, 
chopped monkey skin or lung [30]. Thus, a histamine feedback 
mechanism controls the release of basophil and mast cell me-
diators in vivo. Histamine operating through histamine 2-recep-
tors also controls the function of other inflammatory cell types, 
and this fact should be kept in mind in evaluating patients on 
the histamine 2-antagonists [31,32]. 
Another potentially important element in the control of 
basophil function has recently been described by Marone in 
this laboratory. He found that adenosine increases leukocyte 
cyclic AMP levels and inhibits mediator release. Perhaps more 
interesting is the parallel observation that human serum, when 
added together with the adenosine deaminase inhibitor erythl'o 
9(2-hydl'oxy-3-monyl) adenine (ENHA), also is a potent inhib-
itor of mediator release [45]. These observations suggest that 
physiological levels of adenosine in body fluids or in serum are 
major elements in the control of basophil and perhaps mast cell 
mediator release. It is well appreciated that histamine, again 
acting thl'ough histamine 2-receptors, controls many elements 
of lymphocyte function [33]. Thus, the linkage between a lack 
of adenosine deaminase and severe combined immunologic 
deficiency may well have as a pathogenetic element lymphocyte 
abnormalities that occur as a result of aberrations in the secre-
tion of histamine [34]. 
Little is known about the mechanism of mediator secretion 
beyond the described control by cyclic AMP. There is evidence 
that the microtubular system is necessary for secretion and that 
the aggregation of microtubules into a functional state is in-
versely related to the level of cyclic AMP [35]. Attempts to 
define some of the biochemical steps leading to granule exter-
iorization have been made both with respect to the mast cell 
and to the basophil, but these attempts have simply served to 
illustrate the areas in which there is a lack of detailed infor-
mation [36,37]. 
THE SIMILARITIES BETWEEN BASOPHILS AND 
NEUTROPHILS 
Having focused upon the similarities between basophils and 
mast cells, 2 cells derived from different progenitors, we will 
now explore the functional relationships between 2 inflaD1ma-
tory cells derived from the same stem cell, i.e., basophils and 
neutrophils. Interest in the latter cell type came from the 
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FIG 4. Augmentation of antigen-induced basophil histamine release 
by serum-treated, washed zymosan particles (Zx) (2 mg/mI) that had 
no effect alone. The brackets indicate the SD. 
observation that highly purified human neutrophils were able 
to generate SRS-A when stimulated by a calcium flux induced 
by an ionophore [38]. Neutrophils also released a low-molecu-
lar-weight eosinophil chemotactic factor similar to ECF-A on 
standard phagocytic stimulation with aggregated IgG or serum-
treated zymosan particles [39]. Thus, the neutrophils were 
found to contain some of the same mediators that had until 
that time been associated with basophils. Conversely, using 
first the basophils from the patient with chronic myelocytic 
leukemia and, more recently, from people with normal baso-
phils, Dr. Thomas has been able to demonstrate that basophils 
contain beta-glucuronidase, an enzyme usually associated with 
the neutrophil granules. In spite of the similarity in ontogeny 
and in the granule associated mediators, the stimuli that induce 
secretory function in the 2 cell types are completely different. 
The polymorphonuclear cell cannot respond to antigenic stim-
ulation and basophils cannot respond to phagocytic stimuli. 
Surprisingly, however, the same phagocytic stimuli that fail to 
induce basophil mediator release are able to markedly poten-
tiate the response of the cell to antigen or anti-IgE [45]. Thus, 
although zymosan and aggregated IgG by themselves have no 
effect, they can more than double the response of basophil to 
antigen or anti-IgE stimulation (Fig 4). This ability does not 
seem to be the result of phagocytosis, but of effects on the cell 
membrane that occur as a result of occupancy of Fc or C 
receptors. Although it has been known that basophils contain 
receptors for IgG, it has not been appreciated that they have a 
complement receptor [40]. This seems likely, however, since 
the preparation of zymosan particles without serum or with 
EDTA-treated serum completely abolishes theil' effect [45]. C3-
deficient serum also fails to prepare zymosan particles for 
enhancement of IgE -mediated histamine release. Thus, it may 
be suggested that the basophils contain a C3b receptor. Not 
surprisingly, a similar receptor has recently been described on 
rat mast cells [41]. 
CONCLUSION 
The in vivo importance of the basophils in defense or in 
pathogenetic mechanisms is unclear. We have attempted to 
discuss some elements of theil' function and to indicate som e 
areas in which they may playa significant role. The observation 
by Dvorak and Askenase that basophils can enter tissue spaces 
expands the potential range of action for these cells. Perhaps 
the best way to appreciate the function of basophils is to view 
them as an interface between foreign antigens and a variety of 
inflammatory processes. Thus, basophils serve as the only 
known link between immune stimuli and some of the serum 
systems t hat participate in inflammation, such as activation of 
the kallikreinkinin system. On the other hand , activated serum 
systems such as complement may interact with basophils; this 
possibility is perhaps best illustrated by the recent observation 
Vol. 71, No.1 
that split fragments of C3 and C5, the C3a and C5a anaphyla-
toxins, can cause mediator release from human basophils [42]. 
The role of the basophil in immediate hypersensitivity phenom-
ena is, of course, one of the few functions that has been firmly 
established. But the work of Dolovich et al [46] and Solley et 
al [47] on late IgE-mediated reactions clea.rly demonstrates that 
basophil-derived mediators directly influence subacute and 
chronic inflammation, and we have attempted in this discussion 
to illustrate some of the ways in which these interactions may 
occur. Clearly, the complex interrelationships between baso-
phils, the serum cascade systems, neutrophils, and lymphocyte 
requil'e further study. 
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